Literature DB >> 6580255

Establishment and properties of vincristine-resistant human myelogenous leukemia K562.

T Tsuruo, H Iida, E Ohkochi, S Tsukagoshi, Y Sakurai.   

Abstract

A vincristine (VCR)-resistant subline of human K562 myelogenous leukemia was established in vitro, and several clones with different susceptibilities to VCR were isolated by the limiting dilution technique. The most resistant clone (H-1) had a 17-fold greater resistance to VCR when compared to the parent K562 cells. The clone gradually lost the resistance during prolonged culture in vitro. These clones generally accumulated smaller amounts of VCR in their cells as compared to the parent cells. The size of H-1 clone cells was almost the same as that of the parent cells. The numbers of potential binding sites of VCR in the K562 cells and the resistant H-1 clone were almost the same. Similar results were obtained for P388 and its VCR-resistant subline. The cells derived from the VCR-resistant H-1 clone were highly cross-resistant to vindesine and moderately resistant to vinblastine. Cells derived from clone H-1 exhibited marginal degrees of cross-resistance to adriamycin, maytansine and VP-16-213, whereas VCR-resistant P388 leukemia cells exhibited significant resistance to these agents, especially to maytansine.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6580255

Source DB:  PubMed          Journal:  Gan        ISSN: 0016-450X


  12 in total

1.  Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies.

Authors:  H Hamada; T Tsuruo
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

2.  In vitro and in vivo modulation by rhizoxin of non-P-glycoprotein-mediated vindesine resistance.

Authors:  H Arioka; K Nishio; Y Heike; S Abe; N Saijo
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

3.  Decreased expression of the amplified mdr1 gene in revertants of multidrug-resistant human myelogenous leukemia K562 occurs without loss of amplified DNA.

Authors:  Y Sugimoto; I B Roninson; T Tsuruo
Journal:  Mol Cell Biol       Date:  1987-12       Impact factor: 4.272

4.  Resistance to thapsigargin-induced intracellular calcium mobilization in a multidrug resistant tumour cell line.

Authors:  Karen Wagner-Souza; Juliana Echevarria-Lima; Louise A P Rodrigues; Marcelo Reis; Vivian M Rumjanek
Journal:  Mol Cell Biochem       Date:  2003-10       Impact factor: 3.396

Review 5.  Differing patterns of cross-resistance resulting from exposures to specific antitumour drugs or to radiation in vitro.

Authors:  B T Hill
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

6.  Relationship between multidrug resistant gene expression and multidrug resistant-reversing effect of MS-209 in various tumor cells.

Authors:  M Baba; O Nakanishi; W Sato; A Saito; Y Miyama; O Yano; S Shimada; N Fukazawa; M Naito; T Tsuruo
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

7.  Two members of the mouse mdr gene family confer multidrug resistance with overlapping but distinct drug specificities.

Authors:  A Devault; P Gros
Journal:  Mol Cell Biol       Date:  1990-04       Impact factor: 4.272

Review 8.  Multidrug resistance in chronic myeloid leukaemia: how much can we learn from MDR-CML cell lines?

Authors:  Vivian M Rumjanek; Raphael S Vidal; Raquel C Maia
Journal:  Biosci Rep       Date:  2013-11-25       Impact factor: 3.840

9.  Expression of P-glycoprotein mRNA in human gastric tumors.

Authors:  Y Sugimoto; N Asami; T Tsuruo
Journal:  Jpn J Cancer Res       Date:  1989-10

Review 10.  Mechanisms of multidrug resistance and implications for therapy.

Authors:  T Tsuruo
Journal:  Jpn J Cancer Res       Date:  1988-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.